GEMZAR + ALIMTA

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Neoplasms

Conditions

Pancreatic Neoplasms, Metastases, Neoplasm

Trial Timeline

โ€” โ†’ โ€”

About GEMZAR + ALIMTA

GEMZAR + ALIMTA is a phase 3 stage product being developed by Eli Lilly for Pancreatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00035035. Target conditions include Pancreatic Neoplasms, Metastases, Neoplasm.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00035035Phase 3Completed

Competing Products

20 competing products in Pancreatic Neoplasms

See all competitors